Financial data provider FactSet (NYSE:FDS) announced better-than-expected revenue in Q4 CY2025, with sales up 6.9% year on ...

Recent performance puts FactSet in context FactSet Research Systems (FDS) has been grinding through a mixed stretch, with the stock down about 40 % over the past year even as revenue and net income ...

Key differences between Corporate FDs and Bank FDs: Now, let's take a look at the differences between corporate FDs and bank FDs according to the information provided by Nirmal Bang's website. Fixed ...

FactSet (FDS) faces margin pressure and slow growth, but robust cash flow and AI potential support a cautiously optimistic outlook. See more here.

FactSet reaffirmed its fiscal 2026 guidance, projecting adjusted EPS of $16.90–$17.60 (versus $17.38 consensus) and sales of ...

On Thursday, stocks roared ahead in reaction to the tame November CPI data in the U.S. Unfortunately, the government shutdown ...

FDS is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of FDS shares has decreased $0.79 since the market last closed. This is a 0.27% ...

The focus in 2026 will be on sustaining the growth momentum despite challenges like tariffs and foreign fund selloff.

Analysts expect the Norwalk, Connecticut-based company to report quarterly earnings at $4.37 per share, compared to $4.37 per share in the year-ago period. The consensus estimate for FactSet ...

Bargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their ...

Omnicell is growing its portfolio of medication management solutions and adherence tools. The Mountain View, Calif.-based company has entered into a definitive agreement with pharmacy software ...